Welcome to IGENOMIX
at ASPIRE 2022

Come into the new age of science

Request information

Welcome to Igenomix

Come into the new age of science

VITROLIFE AND IGENOMIX AT ASPIRE 2022

Explore Vitrolife’s virtual booth at ASPIRE and learn more about how working with us can help you maximise success every step of the way.

In 2021, Vitrolife acquired Igenomix which is a leader in reproductive genetic testing services for IVF clinics, founded in 2011. Together we create a global leader in reproductive health and by combining Igenomix’s portfolio of reproductive genetic testing services with Vitrolife’s best-in-class IVF device portfolio, we will be able to better support clinics and patients across the fertility journey. Visit our booth at ASPIRE to know more.

Visit the congress - Aspire 2022 Go to Vitrolife's Aspire 2022 page

VITROLIFE SYMPOSIUM

“Ways to Optimise and Improve your IVF Outcomes”

Friday, 29th April 2022
01:00 pm – 02:15 pm (GMT+8)

As a part of the scientific program at ASPIRE, Vitrolife is honored to welcome you to a session about Ways to Optimise and Improve Your IVF Outcomes. The program includes:

Optimisation of Workflow and Resource Management Using iDAScore, Dr. Marcos Meseguer
Implantation Failure, Prof. Carlos Simón
The Biology and Clinical Impact of EmbryoGlue, Prof David K. Gardner

Register now

Learn more about our products

Genomics Precision Diagnostics

Endometrial Health

EMBRACE

Screening Diagnostics

Newborn Screening

Learn more about our services

Clinic Portal

Request information

Genomic Precision Diagnostics

We offer new services such as the new Precision Genomic Diagnosis division

We have expanded our reproductive health portfolio with this new comprehensive genetic diagnostic service that covers the entire life cycle and is supported by all available technologies (single gene, CMA, etc.) and it has more than 250 different diagnostic panels:

Single Gene Analysis

Chromosomal Microarrays

Precision Panels

Whole Exome Sequencing

Prenatal genetic diagnosis integral service

Prenatal Genetic Diagnosis is a service that identifies genetic alterations in the fetus that can lead to a disorder during pregnancy or the neonatal period that is clinically actionable.
6-8% of pregnancies are high risk
3-5% of pregnancies show ultrasound findings
3% of newborns present congenital defects

Download clinical sheet

Request information

Endometrial Health

The endometrium matters

The ERA test offers a personalized transfer recommendation in the first biopsy in 90% of the samples analyzed
The ERA test analyzes the 248 genes needed to accurately determine the personalized implantation window for each patient
71% of patients that had a personalized embryo transfer, had a baby after one year
The ERA intelligent algorithm based on Artificial Intelligence can detect 12 hour displacements in the window of implantation
30% of infertile women have pathogenic bacteria in their endometrium: EMMA & ALICE test for a 360º view of endometrial health

Download clinical sheet

Request information

EMBRACE

Embryo Analysis of Culture Environment

A non-invasive test for prioritizing embryo transfer that avoids invasive embryo biopsy, potentially increasing accessibility for a wider patient population.
EMBRACE scores embryos according to their probability of being healthy and viable based on chromosomal information.
The recent identification of embryo cell-free DNA in spent blastocyst media opened a new era of possibilities for non-invasive embryo aneuploidy testing in assisted reproductive technologies.

Download clinical sheet

Yosu Franco, PhD

Laboratory and Scientific Director of Hospital Ruber Internacional, Madrid, Spain

Poster number: P560

Title: Comparative analysis of non-invasive preimplantation genetic testing of aneuploidies (niPGT-A), PGT-A and IVF cycles without aneuploidy testing: preliminary results.

Request information

Screening Diagnostics

CGT our advanced Carrier Genetic test, the most complete Genetic screening test based on Exome sequencing that cover over 2,000 genes that cause more than 2,200 diseases, providing in 20 working days the most accurate test results to future parents giving them the opportunity to make informed decisions and review the range of options available to guide pregnancy and family planning.

Download clinical sheet

Why choose our CS Exome Based?

CLINICAL ADVANTAGE

Allows for testing of All known recessive conditions.
Increases the overall detection rate minimizing the global residual risk.

MATCHING

Matching possible with ALL genetic lab tests in the market.
Simplifies competitor CS panel mirroring as no resequencing is required to provide matching information.

UPGRADES

Any upgrade possible at a later date if required

REANALYSIS

Exome Sequencing offers added value for future analysis of a given patient.
Provides analytical possibilities in an adverse event of a newborn with a genetic condition.

Request information

Newborn Screening

Comprehensive genetic test

Newborn Screening Test (NBS) is a comprehensive genetic test that includes 104 genes analyzed using Next Generation Sequencing (NGS) technologies allowing a direct approach of genetic disorders to reach an accurate diagnosis. It is a screening test of genetic actionable diseases indicated for all newborns and performed during the first days of life.

Download clinical sheet

Diseases with high prevalence rates.
Detect diseases where you can take action to improve prognosis.
Genes selected according to evidence-based medicine.
Availability and access to treatment.

CLINICAL PORTAL

Connecting clinics, specialists, and patients through our digital ecosystem

In Igenomix we want to contribute by making doctor’s daily lives easier. With this idea in mind, we have developed a new Clinic Portal where specialists can manage everything which is necessary to

Request genetic tests
Access and download patient’s results
Request kits
Obtain documentation

Request information

Welcome to IGENOMIX at ASPIRE 2022